# The Stay Study: A Demonstration Project Advancing PrEP Delivery in the San Francisco Bay Area Transgender Community

> **NCT03120936** · PHASE4 · COMPLETED · sponsor: **Public Health Foundation Enterprises, Inc.** · enrollment: 158 (actual)

## Conditions studied

- Transgender Persons
- Pre-Exposure Prophylaxis

## Interventions

- **DRUG:** Emtricitabine / Tenofovir Disoproxil Oral Tablet
- **BEHAVIORAL:** PrEP support

## Key facts

- **NCT ID:** NCT03120936
- **Lead sponsor:** Public Health Foundation Enterprises, Inc.
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-08
- **Primary completion:** 2020-08-27
- **Final completion:** 2020-12-01
- **Target enrollment:** 158 (ACTUAL)
- **Last updated:** 2021-04-21

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03120936

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03120936, "The Stay Study: A Demonstration Project Advancing PrEP Delivery in the San Francisco Bay Area Transgender Community". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03120936. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*